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Abstract
Background: Millettia macrophylla was previously reported to have estrogenic effects and to prevent
postmenopausal osteoporosis in Wistar rats. So, the study deals with the identification of its secondary metabolites
and the evaluation of their estrogenicity and cytotoxicity toward tumoural cells. Thus, 13 known compounds were
obtained from successive chromatographic columns and identified by NMR data compared to those previously
reported.
Methods: In vitro estrogenicity of the isolates and the phenolic fraction (PF) of M. macrophylla were performed by
E-screen and reporter gene assays, while their cytotoxicity was evaluated by Alamar Blue (resazurin) assay. A 3-days
uterotrophic assay and the ability of PF to alleviate hot flushes in ovariectomized adult rats were tested in vivo.
Results: Seven of the 13 secondary metabolites turned to be estrogenic. Only two exhibited cytotoxic effects on
MCF-7 and MDA-MB-231 with CC50 values of 110 μM and 160 μM, respectively. PF induced a significant (p < 0.01)
MCF-7 cells proliferation and transactivated both ERα and ERβ in the reported gene assay at 10−2 μg/mL. In vivo, PF
acted more efficiently than the methanol crude extract, resulting to a significant (p < 0.01) increase in the uterine
wet weight, uterine protein level, uterine and vaginal epithelial height at the dose of 10 mg/kg BW. In addition, PF
reduced the average duration and frequency of hot flushes induced in rat.
Conclusion: These aforementioned results indicate that PF is a good candidate for the preparation of an improved
traditional medicine able to alleviate some menopausal complaints such as vaginal dryness and hot flushes.
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Background
Cancer is a leading cause of death and a major public
concern worldwide. More than 1.1 million people are di-
agnosed every year with cancer among them 410,000
deaths [1]. In developing countries, gynecological and
mammary cancers (breast, uterus, and ovarian) account
for 19 % of cancers worldwide and are among the lead-
ing causes of morbidity and mortality in these countries
[2]. Chemotherapy and surgery remain the major treat-
ments of this ailment although side effects and the treat-
ment expense represent two major difficulties for
affected patients, especially those from Sub-Saharan Af-
ricans. These two factors make approximately 80 % of
the population rely and use medicinal plants for their
primary healthcare problems or as an alternative solu-
tion to cure diseases [3]. Nowadays, there is a recrudes-
cence of interest for the natural alternative such as
medicinal plants and dietary means. Even in developing
countries, this phenomenon is observed because of their
efficacy and toxicity tolerance [4, 5]. So, medicinal plants
are increasingly screened for seeking anticancer hits and
numerous phytoconstituents have already been reported
to be cytotoxic toward breast tumour cells and to pre-
vent or abrogate tumours induced in rats [6–9]. Phytoes-
trogens are plant metabolites with the chemical
structure shaped as that of 17β-estradiol and mimic es-
trogenic actions in mammals [10]. Natural estrogenic
compounds include coumestans, isoflavonoids and flavo-
noids [11, 12]. Since they are endowed with both estro-
genic and antiestrogenic properties, these natural
selective estrogen receptors modulators are now pro-
moted as a preventive alternative against estrogen-
dependent cancers such as breast, ovarian, uterine and
prostate cancers [13].
As part of our continuous search of new phytoestro-
gens, we focused the study on Millettia macrophylla
(Fabaceae), a plant growing in sub-Saharan Africa. It is
used for the treatment of respiratory difficulties, consti-
pation, colds and headaches, jaundice as well as some
physiological disorders related to menopause [14, 15].
There are also evidences suggesting that plants belong-
ing to the genus Millettia can boost the immune system,
and even fight some forms of cancer [16, 17]. Our previ-
ous work showed that M. macrophylla dichloromethane
(DCM) and methanol (MeOH) extracts have estrogen-
like effects on estrogen target organs of ovariectomized
Wistar rats and prevent postmenopausal osteoporosis
[18, 19]. In addition the estrogen-like effects of these ex-
tracts were inhibited in vitro and in vivo by the pure ER
antagonist ICI 182, 780 (Fulvestrant), indicating that
their effects were primarily mediated through ERs [20].
These findings suggest the presence of estrogenic/anties-
trogenic compounds in M. macrophylla helpful for the
treatment of estrogen-dependent cancers, since two
thirds of newly diagnosed invasive breast tumors are
estrogen-dependent [21]. The present study therefore
aimed to identify and isolate the major compounds
present in M. macrophylla and to assess their estrogenic
and cytotoxic effects.
Methods
Plant material and extraction
Stem barks of Millettia macrophylla were collected in
Kumba (South-west Region of Cameroon) in January
2010 and identified at the Cameroon National Herbar-
ium (CNH) (Voucher specimen N°49654/HNC) by the
botanist M. Victor Nana. The well-dried and pulverized
stem bark of this plant (2,500 g) was extracted succes-
sively with DCM and MeOH (10 L of each solvent × 3;
72 h per extraction). Following concentration under re-
duce pressure, 25 g (1 %) of dichloromethane and 53.4 g
(2.14 %) of methanol crude extracts were obtained.
Isolation of compounds from M. macrophylla DCM extract
Eight grams of DCM extract was chromatographed
using a normal phase Medium Pressure Liquid Chroma-
tography (MPLC, BÜCHI Labortechnik AG) conditioned
in a column with metal sheath glass (36 × 460 mm),
adapted to the pressure of work (15 bar). A glass pre-
column was used to reduce the load imposed on the
walls of the column. The stationary phase consisted of
silica gel 60H (granulometry 20–40 μm). The mobile
phase consisted of a binary mixture of solvent of
hexane–dichloromethane–ethylacetate–methanol of in-
creasing polarity by step gradient using the pump Büchi
C-605, to yield 875 fractions collected and combined on
the basis of TLC and HPLC analysis into 40 collective
fractions (F1 – F40). The fractions F5 (50–60; 158.6 mg),
F10 (123–156; 913.2 mg), F14 (299–353, 328.2 mg) and
F18 (439–495, 108 mg) were pure and correspond to
compounds 1, 2, 3, and 4, respectively.
A qualitative evaluation of the fractions by TLC and
HPLC-PDA (using a gradient method with H2O+ 2 %
acetic acid and CH3CN+ 2 % acetic acid) was performed in
order to select fractions rich in flavonoids and isoflavo-
noids. Thus, fractions F15 (354–405; 212.4 mg) were sub-
jected to a preparative TLC developed in c-hex/EtOAc: 70/
30 (v/v) to give 2. From the fraction F25 (838–850; 44 mg),
compound 5 (2.4 mg) was isolated using preparative TLC
developed with c-hex/EtOAc: 70/30 (v/v). The F33 (864)
and F34 (865) were merged (100 mg) and filtered through a
Sephadex LH-20 column (bead size: 25–100 μm). From this
fraction, 74 subfractions were obtained. From subfractions
32–41 (24.7 mg), compound 6 (4.1 mg) was obtained after
purification on preparative TLC, developed in c-hex/
EtOAc: 70/30. Subfractions 42–54 (25 mg) was subjected
to preparative TLC using c-hex/EtOAc: 70/30 (v/v) afford-
ing to compounds 6 (5.7 mg) and 7 (3.3 mg).
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Isolation of compounds from M. macrophylla phenolic
fraction (PF)
In order to maximize phenolic compounds isolation, a M.
macrophylla phenolic fraction (PF) was prepared using
resin enrichment technology. To achieve this goal the
Amberlite XAD-7PH resin (Rhom and Hass, France) was
used. The resin was conditioned with excess of distilled
water and activated in ethanol -EtOH (96.30°) overnight.
EtOH was removed by rinsing the activated resin with dis-
tilled water. Then, 52 g of M. macrophylla MeOH crude
extract were diluted in distilled water and sonicated (Elma-
sonic S100H at 40 °C for 1 h). Further, the obtained solu-
tion was subjected to a separating funnel (2,000 L)
containing 400 mg of Amberlite XAD-7PH resin, rinsed
many times with distilled water and the water-soluble frac-
tion was collected. The phenolics adsorbed by the resin
were eluted using EtOH and the obtained phenolic fraction
was concentrate in a rotavapor to afford 7.16 g of phenolic
fraction (PF).
Six grams of phenolic fraction was chromatographed
using a Medium Pressure Liquid Chromatography (MPLC)
as described above with the slight difference that the col-
umn size was 36 × 460 mm and the applied pressure was
20 bar. The stationary phase consisted of silica gel RP-18
(granulometry 40–63 μm). The mobile phase consisted of
a binary mixture of solvent of water–ethanol of increasing
polarity by step gradient using the pump Büchi C-605, to
yield 693 fractions collected and combined on the basis of
TLC and HPLC analysis into 26 collective fractions. Frac-
tions from F9 to F13 (226–380) were merge (240 mg) and
subjected to a Sephadex LH-20 gel filtration. Compounds
8 (2 mg) and 9 (1 mg) were isolated using preparative TLC
developed with DCM/MeOH (98/02: v/v) of subfractions
77–87 (14.1 mg). Subfractions from 88 to 98 (13.1 mg)
were subjected to preparative TLC developed with DCM/
MeOH (95/05: v/v) to afford compounds 9 (1 mg) and 10
(0.9 mg). Compound 11 (1.7 mg) was obtained after purifi-
cation with preparative TLC developed with DCM/MeOH
(93/07: v/v) of subfractions 104–116 (12.5 mg). From the
initial fractionation, fractions F14 (381–423, 90 mg) and
F15 (424–455, 80 mg) were merged and 160 mg were sub-
jected to a Sephadex gel filtration. After a preparative TLC
developed with c-hex/EtOAc (70/30: v/v), the subfraction
17–27 (12.3 mg) afford to compounds 10 (2 mg) and 12
(1.8 mg). Subfractions 28–43 (20.6 mg) led to compound
12 (1 mg) after purification on a preparative TLC devel-
oped with c-hex/EtOAc (60/40: v/v). The fraction F16
(456–484, 140 mg) was subjected to a silica gel column
(granulometry 40–63 μm). Subfractions 28–130 (10.2 mg)
were subjected to a preparative TLC developed with c-hex/
EtOAc (60/40: v/v) to led compound 10 (1.4 mg). Com-
pound 13 (1.5 mg) was isolated from the subfractions 131–
280 (10.3 mg) in the preparative TLC developed with c-
hex/EtOAc (40/60: v/v).
UHPLC-LTQ-Orbitrap Analysis of Millettia macrophylla
phenolic fraction
The analysis of the phenolic fraction of Millettia macro-
phylla was performed using an Accela Ultra High-
Performance Liquid Chromatography (UHPLC) system
equipped with a mixing pump, an autosampler, and hy-
phenated to a hybrid LTQ-Orbitrap Discovery Mass
Spectrometer (Thermo Scientific, Bremen, Germany).
Stock solution of 100 μg/mL (MeOH/H2O, 50/50, v/v)
of the fraction was prepared and 10 μL injected on a
Hypersil Gold column (100 × 2.1 mm i.d., 3 mm) particle
size, Thermo Scientific, Waltham, MA). The mobile
phase used was aqueous acetic acid 0.1 % (v/v) (solvent
A) and acetonitrile (solvent B). The initial conditions
were 98 % of solvent A and 2 % of solvent B adjusting
linearly to 98 % B in 18 min. This solvent composition
was maintained for 0.9 min (98 % B) followed by a re-
turn to the initial conditions (in 0.1 min) and a re-
equilibration step (1 min) prior to the next run. The flow
rate was set to 500 μL/min.
The mass spectrometer was equipped with electro-
spray ionization (ESI) source and activated in a positive
mode. The analysis was performed in full scan acquisi-
tion and the mass tolerance was set to 5 ppm for all
measurements. The ESI source was operated at a sheath
gas flow rate of 50 arb, auxiliary gas flow rate of 10 arb,
ion spray voltage of 3.5 kV, capillary temperature of
300 °C, capillary voltage of 35 V, tube lens of 110 V.
Xcalibur 2.0.7 software was used for the pre- and post-
acquisition of the results.
General phytochemistry experimental procedures
A Thermo Finnigan HPLC system (ThermoFinnigan,
San Jose, CA) was employed for the profiling of the ex-
tract connected to a Spectral System UV2000 PDA de-
tector. ChromQuest 2.1 software was used for the
management of the data. Nuclear magnetic resonance
(NMR) spectra were obtained on Bruker 600 MHz spec-
trometer using CDCl3 (Sigma Aldrich, Germany) as
solvent. The 2D-NMR experiments (COSY, LRCOSY,
HMQC, HSQC-DEPT135, and HMBC) were performed
using standard Bruker microprograms. ESI-HRMS were
run on a Thermo Scientific LTQ Orbitrap Discovery
mass spectrometer. GC-MS analyses were carried out
using a Hewlett-Packard 5973–6890 GC-MS system op-
erating in the EI mode at 70 eV, equipped with an HP-5
MS capillary silica column (30 m × 0.25 mm i.d.;
0.25 μm film thickness). Sephadex LH-20 (Merck,
Germany) was used as gel filtrate. Precoated TLC silica
60 F254 plates (Sigma Aldrich, Germany) were used for
thin-layer chromatography (0.25 and 2 mm layer thick-
ness for analytical and preparative TLC, respectively).
Spots were visualized using UV light and vanillin–sul-
furic acid reagent.
Zingue et al. BMC Complementary and Alternative Medicine  (2016) 16:421 Page 3 of 17
Chemicals
Serum and antibiotics were purchased from GIBCO (Grand
Island, NY). The 17β-estradiol benzoate (Estr-1,3,5(10)-
trien-3,16α,17β-triol) was obtained from Sigma-Aldrich
(Hamburg, Germany). The 2-[4-(2-hydroxyethyl)piperazin-
1-yl]ethane sulfonic acid (HEPES) was purchased from
Ludwig Biotecnologia Ltda (Alvorada, RS, Brazil). Trypan
blue, Sulforodamine B, Alamar blue and cell culture me-
diums were purchased from Sigma-Aldrich (St. Louis, MO,
USA). Genistein was obtained from “Extrasynthese®”
(Genay, France). Penicillin (xtapen®) was provided by CSPC
Zhongnuo pharmaceutical (Shijiazhuang City, China).
Diclofenac (Dicloecnu®) was provided by ECNU pharma-
ceutical (Yanzhou City, China). The Smart Button Data




The MCF-7 – Human ER-positive breast adenocarcin-
oma cells and the MDA-MB-231– human ER-negative
breast adenocarcinoma cells were obtained from the Rio
de Janeiro Cell Bank (Federal University of Rio de
Janeiro, Brazil).
HEK293T – Human Embryonic Kidney 293 T cells
line that contain the SV40 large T-antigen were pur-
chased from ATCC (The Global Bioresource Center,
Australia). Luciferase reporter construct, ERα and ERβ
expression plasmids were kindly provided by Dr Simon
Chu (Hudson Institute of Medical Research, Australia).
Cells were transfected using Lipofectamine Reagent ob-
tained from Invitrogen (Sydney, Australia).
Animals
Healthy juvenile female Wistar rats aged 3 months ( 150 g)
were obtained from the breeding facility of the Laboratory
of Animal Physiology, University of Yaounde I (Cameroon).
Animals were housed in clean plastic cages at room
temperature (around 25 °C) under natural illumination
(approx. 12 h light/dark). They had free access to a standard
soy-free rat chow and water ad libitum. The composition
of animal diet was: corn (36.7 %), bone flour (14.5 %), wheat
(36.6 %), fish flour (4.8 %), crushed palm kernel (7.3 %), so-
dium chloride (0.3 %) and vitamin complex (Olivitazol® -
0.01 %).
Ethical consideration
Housing of animals and all experiments were approved
by the Cameroon Institutional National Ethic Commit-
tee, which adopted all procedures recommended by the
European Union on the protection of animals used for




MDA-MB-231 cells were cultured in DMEM medium
supplemented with 10 % of fetal bovine serum (FBS).
MCF-7 cells were cultured in RPMI-1640 medium sup-
plemented with 10 % of FBS. HEK293T cells were cul-
tured in DMEM medium supplemented with 10 % fetal
calf serum (FCS). All cell cultures were also supple-
mented with 100 U/mL penicillin, 100 μg/mL strepto-
mycin and 10 mM HEPES. The cell cultures were
maintained at 37 °C in a 5 % CO2 humidified atmos-
phere and pH 7.4. Every two days, cells were passaged
by removing 90 % of the supernatant and replacing it
with fresh medium. In all experiments, viable cells were
checked at the beginning of the experiment by Trypan
Blue dye exclusion test.
Cell viability assay
Cytotoxicity potentials of isolates from M. macrophylla
as well as phenolic fraction were evaluated by Alamar
Blue (resazurin) assay [22], in two independent cellular
systems (MCF-7 and MDA-MB-231). To evaluate the in-
fluence of concentration and time on cytotoxicity, 1 × 104
cells/well were seeded in a 96-well plate in 100 μL of cul-
ture medium. After 24 h to permit their adhesion, cells
were exposed to the 13 compounds isolated from M.
macrophylla (1 to 13) at concentrations ranging from 100
to 500 μM. M. macrophylla phenolic fraction (PF) was
also tested at concentrations of 100 and 500 μg/mL for
24 h. The CC50 value (cytotoxic concentration, which
means concentration required to reduce the cell number
by 50 %) was determined only with promising compound
by nonlinear regression analysis of the logarithm of con-
centration in function of the normalized response (per-
centage of cell viability) using the software GraphPad
Prism 5.0. Each experiment was performed in at least trip-
licate and repeated three times.
E-screen assay
In order to evaluate estrogenic-like effects of isolates from
M. macrophylla a simple and sensitive E-screen cell prolif-
eration assay was performed with human ER-positive breast
adenocarcinoma cells (MCF-7). This assay determines the
estrogenicity/antiestrogenicity of compounds indirectly
through measurement of the proliferation of MCF-7 cells.
For this purpose, the technique slightly modified by
Resende et al. [23], from the originally described by Soto et
al. [24] was used. Briefly, cells were trypsinized and seeded
in 24-well plates at an initial concentration of 20,000 cells
per well in 10 % FBS in RPMI. After 24 h of incubation
(37 °C, 5 % CO2) to permit their adhesion, cells were
washed with phosphate-buffered saline (PBS) and the
Serum Replacement 2 (0.5×) supplemented phenol
red-free RPMI was substituted for the seeding medium.
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M. macrophylla compounds were added to the experi-
mental medium at concentrations from 0.1 to 10 μM. For
antiestrogenicity tests, before incubation, 1 × 10−8 M of
17β-estradiol was added to the wells. Steroid-free experi-
mental medium consisted to negative control while cells
treated with 1 × 10−8 M of 17β-estradiol served as
positive control. There were also a solvent control
(DMSO at 0.01 %) and a medium control (10 % FBS
in RPMI). The assay was stopped after 144 h by removing
the medium from wells, fixing the cells, and staining them
with sulforhodamine-B (SRB). Briefly, cells were treated
with cold 10 % trichloracetic acid and incubated at 4 °C for
1 h. Then, the cells were washed four times with tap water
and dried. Furthermore, cells were stained during 30 min
with 0.057 % (w/v) SRB dissolved in 1 % acetic acid. Wells
were rinsed four times with 1 % acetic acid and air dried.
Bound dye was solubilized with 10 mM Tris base (pH 10.5)
in a shaker. Finally, aliquots were read in a Biotek EL800
Multiscan apparatus (Winoosky, USA) at 510 nm.
The results expressing the estrogenic activity were
showed as mean ± standard error of mean of the prolif-
erative effect (PE), which represents the maximum pro-
liferation induced by the compounds. This parameter
was calculated according to Schiliro’et al. [25], and is the
ratio between the highest cell number achieved with the
sample or 17β-estradiol and the cell number in the solv-
ent control (0.01 % DMSO): PE =max cell number of
sample/cell number of DMSO control.
The estrogenic activity of a sample was determined as
the relative proliferative effect (RPE%). The RPE com-
pares the maximum proliferation induced by a sample
with that induced by 17β-estradiol: RPE% = [PE for sam-
ple/PE for 17β-estradiol] × 100 [23].
Transfections and luciferase assays
Due to the available quantity of isolates of M. macro-
phylla, only stigmastenone (3) and phenolic fraction
(PF) has been deal with their capacity to activate estro-
gen receptors α and β, in cell-reporter gene assays. The
Human Embryonic Kidney 293 T cell line (HEK293T)
was transiently transfected with adequate plasmids using
Lipofectamine Reagent as previously described by
Zingue et al. [18]. They were then treated with different
concentrations [10−9 to 10−5 M for stigmastenone (3)
and 10−5 to 10−1 μg/mL for phenolic fraction] for 24 h.
Cells treated with E2 (10 nM) alone served as positive
control. Luciferase activity was measured and normal-
ised against β-galactosidase activity as previously
described [18].
In vivo experiments
The 3-day uterotrophic assay
To achieve this goal, 35 female Wistar rats received a single
intramuscular dose of long acting penicillin and diclofenac
(10 mg/kg and 3 mg/kg respectively) the day before ovari-
ectomy. Thereafter they were bilaterally ovariectomized
(OVX) using the dorsal approach [26] under Diazepam and
ketamin anesthesia (respectively 10 mg/kg and 50 mg/kg
BW; i.p.). After 14 days of endogenous hormonal decline,
animals were randomly distributed into seven groups of five
animals each (n = 5). The first group or OVX group re-
ceived vehicle only (corn oil) and the second group received
estradiol Benzoate (E2B) as standard drug at the optimal
dose of 2 μg/kg per day. The third group received genistein
at the dose of 10 mg/kg. The remaining four groups re-
ceived either the phenolic fraction (PF) at doses of 1, 10
and 100 mg/kg or the methanol crude extract (MeOH) of
M. macrophylla at dose of 100 mg/kg. All treatments were
administered by subcutaneous route (0.3 mL/150 g) for
3 days. Twenty-four hours after the last administration, ani-
mals were euthanized by decapitation. The uterine wet
weight, total protein levels in uterine, uterine and vaginal
epithelial heights and mammary gland were assessed as
described before by Zingue et al. [20].
Measurement of hot flushes
Data loggers were used to monitor the core temperature
changes in the animals at 2 min intervals for 72 h, as previ-
ously described by Zingue et al. [27]. In this study, data log-
gers were preset to start measuring core temperatures 12 h
before the beginning of the treatment until the end of treat-
ment. Twenty acclimatized rats were either sham-operated
(Sham) or bilaterally ovariectomized (OVX) as described
above, and at the same time underwent the implantation of
a data logger protected in sterilized neutral wax into their
abdominal cavities. After 14 days of endogenous hormonal
decline, animals were randomly distributed into four
groups of five rats each (n = 5). They were treated for 3 days
with corn oil as vehicle (OVX and Sham groups), estradiol
benzoate (E2B) (2 μg/kg BW per day), and the active dose
of the phenolic fraction (10 mg/kg BW per day). All treat-
ment was given by subcutaneous route (0.3 mL/150 g) and
lasted 3 days. Twenty four hours after the last administra-
tion, animals were euthanized by decapitation, and the data
loggers recovered. Data (central body temperature) was re-
trieved from loggers into excel spreadsheets and analyzed
using the ACR Trend Reader for Smart Button Software.
Hot flushes were considered for any internal tempera-
tures ≥ 38 °C. The total number of hot flushes, the average
of these hot flush durations and the frequency of hot
flushes were determined as described before [27].
Histological analysis
Using the complete Zeiss equipment consisting of a
microscope Axioskop 40 connected to a computer where
the image was transferred, and analyzed with the
MRGrab1.0 and Axio Vision 3.1 softwares, all provided
by Zeiss (Hallbermoos, Germany), the histomorphology
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of the mammary glands, as well as the uterine and vagi-
nal epithelial heights, were assessed from 5-μm sections
of paraffin-embedded tissues following hematoxylin-
eosin staining.
Biochemical analysis
Total uterine protein levels were determined in uteri using
colorimetric methods described by Gonal et al. [28].
Statistical analysis
Results are presented as means ± standard error of mean
(SEM). In vitro experiments were performed in tripli-
cates and repeated three times. All formulas and func-
tions were calculated with Microsoft Excel software.
Data analysis was performed with GraphPad Prism 5.0
software, using the ANOVA test followed by the Dun-
nett’s post hoc test. Differences were considered signifi-
cant at a probability level of 5 % (p < 0.05).
Results
Phytochemical analysis of M. macrophylla
Identification of M. macrophylla isolates
A total of 13 secondary metabolites were isolated from
M. macrophylla stem barks extracts. The structures of 1,
2, and 5–13 were elucidated by 1D & 2D NMR as well
as HRMS and by comparison to previously reported data
(Additional file 1). Compounds 3 and 4 structures were
determined by GC-MS. The M. macrophylla isolates
(Fig. 1) were identified as lupenone (1) [29], lupeol (2)
[30], stigmastenone (3) [31], palmitic acid (4) [32], daid-
zein dimethylether (5) [33], formononetin (6) [34], afro-
morsin (7) [34], secundiferol I (8) [35], 2′-
hydroxyformononetin (9) [36], pisatin (10) [37], flemi-
chapparin B (11) [38], dihydrocoumestrol dimethyl ether
(12) [39] and variabilin (13) [40].
UHPLC-LTQ-Orbitrap Analysis of Millettia macrophylla
phenolic fraction
The profiling of the phenolic fraction of Millettia macro-
phylla revealed the presence of the several secondary
metabolites covering a wide polarity range (Fig. 2).
Amongst others, 12 compounds could be tentatively
identified. Chromatographic and spectrometric features
such as retention time (Rt), high resolution quasi-
molecular ion (HRMS, m/z), suggested elemental com-
position, Ring Double Bond equivalent (RDBeq) were
incorporated to the identification procedure. Specifically,
six isoflavonoids (daidzein, daidzein dimethyl ether, biocha-
nin A, 7-methyl tectorigenin, formononetin, afromorsin),
three pterocarpans (maackiain, pisatin, flemichapparin B),
one coumestan (coumestrol methyl ether), and one simple
phenolic (2,4,6-Trimethoxyphenol) could be detected
(Table 1). However, three compounds initially isolated from
the phenolic fraction namely secundiflorol I, glycinol
dimethyl ether, and dihydro-coumestrol dimethyl ether
were not identified in the UHPLC-MS profile probably due
to their minor concentration in the whole fraction.
Effects of M. macrophylla isolates on cell viability
The cytotoxic potential of M. macrophylla isolates is
depicted in Table 2. No cytotoxic effects were found with
compounds 1, 3–5, 9–12 up to 500 μM in both
MCF-7 and MDA-MB-231 cells. However, only 2
(110 μM) and PF (452 μg/mL) induced a reduction of
50 % of MCF-7 cells viability. MDA-MB-231 cells
were more sensitive to the isolates than MCF-7 cells.
CC50 values of 2, 6, 7, 8, 13 and PF against MDA-
MB-231 cells were 160 μM, 342 μM, 224 μM,
457 μM, 296 μM, and 327 μg/mL, respectively.
In vitro estrogenic effects of M. macrophylla isolates
E-screen assay
Results of the in vitro estrogenic potencies of M. macro-
phylla isolates are illustrated in Table 3 and Fig. 3. Lupeol
(2), stigmastenone (3), formononetin (6), afromorsin (7),
pisatin (10), flemichaparin B (11), variabilin (13) and phen-
olic fraction (PF) of M. macrophylla induced a significant
(p < 0.05 to p < 0.001) proliferation of MCF-7 cells such as
17β-estradiol (p < 0.001) as compared to DMSO control.
Moreover, the rank order of the ability of these compounds
to induce MCF-7 proliferation was: 13 > 7 > 10 > 3 > 11 >
6 > 2 > phenolic fraction. Although it has been observed
decreased of MCF-7 cells yield with increasing concentra-
tion of compounds, no significant antiestrogenic effect was
observed in this assay (data not shown).
Luciferase assay
It was found in this work that stigmastenone (3) signifi-
cantly (p < 0.01) transactivated the ERα only at the con-
centration of 10−9 M and this transactivation seems to
decrease while its concentration rises up (Fig. 4a). In
other hand, 3 failed to transactivated or antagonized the
estrogen activity on ERβ (Fig. 4b). As far as M. macro-
phylla phenolic fraction is concerned, it induced a sig-
nificant transactivation of the ERα as well as the ERβ at
concentrations of 10−3 (p < 0.01) and 10−2 μg/mL (p <
0.001), while this effect disappear at the concentration of
10−1 μg/mL (Fig. 4c). Moreover, the phenolic fraction of
M. macrophylla seems to be antagonistic to E2 at the
lower (10−5 and 10−4 μg/mL) and higher (10−1 μg/mL)
concentrations, while it exhibited a synergistic activity
with E2 at the concentration of 10−2 μg/mL in
HEK293T-ERα. A significant (p < 0.001) antiestrogenic
activity was also observed with the phenolic fraction of
M. macrophylla on HEK293T-ERβ at the concentration
of 10−2 μg/mL (Fig. 4d).
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In vivo estrogenic effects of M. macrophylla phenolic
fraction
Effects on uterus
Figure 5 showed that E2B induced a significant increase
(p < 0.001) in the uterine wet weight (Fig. 5a) as well as
total protein levels in the uterus (Fig. 5b) as compared
to the OVX group. Genistein at the dose of 10 mg/kg
did not increase the uterine wet weight while it induced
a non-significant increase in uterine total protein levels.
The phenolic fraction led to a significant increase (p <
0.05) in the uterine wet weight (693.31 ± 52.04 vs 399.31
± 31.12 mg/kg in OVX group) only at the dose of
10 mg/kg and in the uterine total protein level at the
dose of 10 (4.0 ± 0.54 vs 3.1 ± 0.02 mg/mL in OVX
group) and 100 mg/kg (3.6 ± 0.08 vs 3.1 ± 0.02 mg/mL in
OVX group), while the methanol crude extract did not
changes the uterine wet weight.
Figure 5d represents the micrographs of the uterus fol-
lowing 3 days of treatment with different substances. It
can be observed that the uterine epithelium of OVX ani-
mals consisted to one layer of very flattened cuboidal
cells while, animals treated for 3 days with E2B present
epithelium composed with large columnar cells. The
measurements of the uterine epithelia height showed
that the E2B and genistein induced a significant increase
(p < 0.001 and p < 0.01) (Fig. 5c) as compared to the
Fig. 1 Structure of compounds isolated from M. macrophylla
Fig. 2 Base peak chromatogram of Millettia macrophylla phenolic fraction recorded in UHPLC-ESI (+)-LTQ-Orbitrap
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OVX group. M. macrophylla phenolic fraction has in-
creased uterine epithelium height (6.15 ± 0.87 vs 3.54 ±
0.21 μm; p < 0.01) at the dose of 10 mg/kg more than
methanol extract at the dose of 100 mg/kg (5.68 ± 0.32 vs
3.54 ± 0.21 μm, p < 0.05) as compared to the OVX group.
Effects on vagina
Analysis of vagina’s microphotographs from different
treatment groups are shown in Fig. 6a. The vagina epi-
thelium of OVX animals is limited to the germinal layer
(Ge), consisting of 5–6 cell layers, whereas the vaginal
epithelium of animals treated for 3 days with E2B be-
came stratified. Similar stratification coupled with vagi-
nal cornification was observed also in animals treated
with the phenolic fraction at the dose of 10 mg/kg (p <
0.01). Furthermore, the measurement of vaginal epithe-
lial height in different treated groups showed that the
E2B induced a significant increase (p < 0.001) in the va-
ginal epithelial height as compared to the OVX group
(Fig. 6b). A significant increase in the vaginal epithelium
height was observed after administrating PF at doses of
10 and 100 mg/kg as well as the methanol extract of M.
macrophylla at the dose of 100 mg/kg. However it can
be noted that the increment induced by phenolic frac-
tion (15.63 ± 3.46 vs 4.47 ± 0.51 μm, p < 0.01) was greater
than that observed with the methanol extract (13.61 ±
1.02 vs 4.47 ± 0.51 μm, p <0.05) as compared to the
OVX group.
Table 1 Chromatographic and spectrometric characteristics of secondary metabolites identified in Millettia macrophylla phenolic
fraction using UHPLC-ESI (+)-LTQ-Orbitrap
Peak Rt (min) Experimental m/z Theoretical m/z Δ (ppm) RDB [M + H]+ Assignment
1 1.61 185.0804 185.0808 −2.352 3.5 C9H13O4 2,4,6-Trimethoxyphenol
2 2.81 255.0646 255.0652 −2.452 10.5 C15H11O4 Daidzein
3 3.97 285.0750 285.0757 −2.491 10.5 C16H13O5 Maackiain
4 6.53 285.0753 285.0757 −1.614 10.5 C16H13O5 Biochanin A
5 6.69 315.0856 315.0863 −2.173 10.5 C17H15O6 Pisatin
6 7.68 315.0855 315.0863 −2.649 10.5 C17H15O6 7-Methyl tectorigenin
7 8.24 269.0801 269.0808 −2.696 10.5 C16H13O4 Formononetin
8 8.39 299.0908 299.0965 −1.939 10.5 C17H15O5 Afromorsin
9 8.75 297.0751 297.0757 −2.289 11.5 C17H13O5 Flemichapparin B
10 10.12 283.0957 283.0965 −2.775 10.5 C17H15O4 Daidzein dimethyl ether
11 10.70 283.0594 283.0601 −2.508 11.5 C16H11O5 Coumestrol methyl ether
Table 2 Cytotoxicity of isolates of M. macrophylla as well as phenolic fraction toward breast cancer cells
CC50
Code Name of compounds MCF-7 cells MDA-MB-231 cells
1 lupenone >500 >500
2 lupeol 110 160
3 stigmastenone >500 >500
4 palmitic acid >500 >500
5 daidzein dimethylether >500 >500
6 formononetin >500 342
7 afromorsin >500 224
8 secundiferol I >500 457
9 2’ OH-formononetin >500 >500
10 (+)-pisatin >500 >500
11 flemichapparin B >500 >500
12 dihydrocoumestrol dimethylether >500 >500
13 variabilin >500 296
PF phenolic fraction 452 327
MCF-7 and MDA-MB-231 cells were incubated with increasing concentration (100–500 μM) of isolates of M. macrophylla and phenolic fraction -PF (100–500 μg/mL) for
24 h. Cell viability was evaluated by Alamar blue assay. The CC50 was determined when applicable by nonlinear regression analysis of the logarithm of concentration in
function of the normalized response (percentage of cell viability). Values are in μM or μg/mL mean of three independent experiments. The Bold data reflect the exact
cytotoxic concentration (CC50)
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Effects on mammary gland
The microphotographs of mammary glands (Fig. 7) re-
vealed that OVX animals exhibited smaller acini with
non-differentiate lumen of acini, low connective paren-
chyma while, adipose tissue is abundant. The E2B treat-
ment induced an increase in the size of acini as well as
the lumen of acini, which appear well differentiated
compared to the OVX group. It can be also observed
the presence of abundant eosinophil secretions in the
lumen of the acini. The treatment with genistein in-
duced such effects although the arising of the eosinophil
secretions in the lumen of acini was low. As far as phen-
olic fraction and methanol extract of M. macrophylla are
concerned, they induced an increase in the lumen of the
acini at all tested doses as compared to OVX group.
However eosinophil secretions were observed only in
animal’s group treated with phenolic fraction at the dose
of 10 mg/kg.
Effects on hot flushes
Two weeks after oophorectomy, the total number of hot
flushes (p < 0.05, Fig. 8a) as well as the average duration
of hot flushes (p < 0.01; Fig. 8b) were significantly in-
creased in the OVX group compared to the normal
group (Sham). A significant decrease in the number (p <
0.05) and in the average duration (p < 0.01) of hot
flushes was observed in the E2B treated group. After
3 days of treatment, the phenolic fraction at the dose of
10 mg/kg induced a significant decrease (p < 0.05) in the
average duration of hot flushes while, it failed to reduce
the total number of hot flushes. As compared to the
normal group (Sham), OVX animals showed a signifi-
cant increase (p < 0.01) in the frequency of hot flushes
(Fig. 8c). As expected, E2B induced a significant de-
crease (p < 0.01) in the frequency of hot flushes as com-
pared to OVX group. Such effects were also observed
with phenolic fraction of M. macrophylla at a dose of
10 mg/kg (p < 0.01).
Discussion
In order to contribute to a better understanding of the
previous reported estrogenic/antiestrogenic properties of
M. macrophylla [18–20], its major components were
isolated. As striking observation, it was noted that most
Table 3 Effects of isolates of M. macrophylla in MCF-7 cells
proliferation assay
Code Name of compounds Concentration PE RPE (%)
DMSO Control - 1 54.2
E2B 17β-estradiol 10 nM 1.84 100
1 Lupenone 0.1 μM 1.38 75
1 μM 1.22 66.48
10 μM 0.47 25.53
2 lupeol 0.1 μM 1.52 82.45
1 μM 1.26 68.62
10 μM 1.19 64.36
3 stigmastenone 0.1 μM 1.63 88.30
1 μM 1.29 70.21
10 μM 0.76 41.49
4 palmitic acid 0.1 μM 1.36 73.94
1 μM 1.13 61.17
10 μM 0.65 35.11
5 daidzein dimethylether 0.1 μM 1.29 70.21
1 μM 1.33 72.34
10 μM 0.90 48.93
6 formononetin 0.1 μM 1.55 84.04
1 μM 1.05 56.91
10 μM 0.67 36.17
7 afromorsin 0.1 μM 1.83 99.47
1 μM 1.21 65.96
10 μM 0.66 35.64
8 secundiferol I 0.1 μM 1.17 63.83
1 μM 1.33 72.34
10 μM 0.68 36.70
9 2’ OH-formononetin 0.1 μM 1.08 58.51
1 μM 0.99 53.72
10 μM 0.65 35.11
10 pisatin 0.1 μM 1.70 92.02
1 μM 1.21 65.96
10 μM 0.66 35.64
11 flemichapparin B 0.1 μM 1.57 85.11
1 μM 1.31 71.28
10 μM 0.82 44.68
12 dihydrocoumestrol DME 0.1 μM 1.23 67.02
1 μM 1.16 62.76
10 μM 0.81 44.15
13 glycinol dimethylether 0.1 μM 2 108.51
1 μM 1.38 75
10 μM 0.88 47.87
Table 3 Effects of isolates of M. macrophylla in MCF-7 cells
proliferation assay (Continued)
PF Phenolic fraction 0.1 μg/mL 1.49 80.85
1 μg/mL 1.17 64.36
10 μg/mL 0.55 29.78
DMSO negative control, E2B positive control, PE proliferative effect calculated
as the effect on solvent control, RPE relative proliferative effect, compares the
maximum proliferation induced by a sample with that induced by 17β-
estradiol. The Bold data represents the values considerate as estrogenic
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of these compounds belonging to the flavonoids group,
specifically, isoflavone, pterocarpan and coumestan sub-
groups, which are well known as phytoestrogens.
Although the uterotrophic assay in rodents is a good
tool to assess estrogenic potency of xenobiotics, this
method is not suitable for the screening of large sus-
pected estrogenic chemicals [41]. We have therefore
used the biologically equivalent E-screen assay described
by Soto et al. [24] and modified by Resende et al. [23].
This assay compares the cell yield between cultures of
MCF-7 cells treated with estradiol and cultures treated
with different concentrations of substances suspected to
endow estrogenic properties. It was noted in this study
that 7 out of 13 isolated compounds from M. macro-
phylla induced MCF-7 cells proliferation such as 17β-
estradiol in the following rank order: 13 > 7 > 10 > 3 >
11 > 6 > 2 > phenolic fraction. The E-screen assay mea-
sures the direct cell proliferation, which is acknowledged
Fig. 3 Effects of lupeol (2), stigmastenone (3), formononetin (6), afromorsin (7) (a) and of pisatin (10), flemichapparin B (11), variabilin (13),
phenolic fraction (PF) (b) from M. macrophylla on MCF-7 cells proliferation. The effect of compounds and phenolic fraction was investigated by
measuring E-screen assay. The relative MCF-7 cells yields (PE) were measured in the presence of DMSO (0.01 %), 17β-estradiol (10 nM), compounds
and phenolic fraction from M. macrophylla. PE =max cell number of sample/cell number of DMSO control. * p < 0.05, ** p < 0.01, *** p < 0.001 as
compared with DMSO
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as hallmark of estrogenicity [24]. Indeed, the MCF-7 cells
proliferation is the reliable estrogenic potency because this
cell line is ER positive and it expresses aromatase and 5 α-
reductase enzymes, which allows it to convert androgens
to estrogens [23, 41]. These authors reported that a relative
proliferative effect (RPE) ≥ 80 corresponds to estrogenic ac-
tivity and suggest that the compound may have agonistic
activity to ERα. However, it is worthwhile to highlight that
the MCF-7 cells can elicit an estrogen-induced response
involving both genomic and non-genomic pathways [25].
Hence, such as in in vivo condition, the MCF-7 cells prolif-
eration observed in E-screen assay is not limited to the
activation of ERs [23].
It is well documented that some chemical features in
the structure of flavonoids are required to obtain an es-
trogenic response [42]. A particular note was aroused on
the hydroxyl group at position 4′ which promotes the
estrogenic activity and the estrogenic potency [43]. Ac-
cordingly, the lack of free hydroxyl group at position 4′
or 7′ in 5 might explain its weak affinity for ERs. Indeed,
Khan et al. [44] showed that 3,4′,-dimethoxy daidzein
had no estrogenicity. This result is consistent with the
observation made in this work with 5. However, they re-
ported that it endow positive skeletal effects in osteope-
nic rats. This might account for the preventive effect
previously observed with M. macrophylla in postmeno-
pausal osteoporosis [19]. The estrogenic activity of M.
macrophylla could be explained in part by the presence
of 6, which activates the expression of the estrogen-
responsive reporter gene in human breast cell line MCF-
7 in a concentration-dependent manner (0.5–500 μM).
Moreover, this activation was inhibited by estrogen an-
tagonist (ICI 182, 780 at 100 nM) [45]. Furthermore, au-
thors have reported that formononetin induced the
proliferation of MCF-7 breast cancer cells, which is con-
sistent with our observations. Other compounds that
might contribute to the estrogenicity of M. macrophylla
are 13 and 10. In fact, 10 has been reported to have a
weak affinity to ERα [46] while glycinol an analogue of
13 found in M. macrophylla displayed estrogenic effect
by induction of MCF-7 cells proliferation at concentra-
tion ranging from 1 to 10 μM [47]. These results are
consistent with the obtained results with variabilin in
this study. In addition, authors showed that glycinol has
a high affinity for both ERα (IC50 = 13.8 nM) and ERβ
(IC50 = 9.1 nM). 11, 3 and 2 are described for the first
time as estrogenic in this work. 11 is structure related to
10, this can explain its estrogenic activity. As far as stig-
mastenone and lupeol are concerned, they are triterper-
noids, and there is little reports in the literature dealing
Fig. 4 Effects of stigmastenone (3) and M. macrophylla phenolic fraction (PF) on the activation of estrogen α and β receptors in HEK293T cells. The
effect of these substances on estrogen α and β receptors activity in the transiently transfected HEK293T-ERα and HEK293T-ERβ cells was investigated
by measuring reporter gene-coupled luciferase activity. The relative luciferase units (RLU) were measured in the presence of EtOH (0.1 %), E2 (10 nM),
stigmatenone (3) as well as M. macrophylla phenolic fraction co-treated with E2. ** p < 0.01; *** p < 0.001 as compared to EtOH control; ### p < 0.001
as compared with E2 control
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the estrogenic activity of triterpernoids. However, triter-
pernoid glycosyl such as glycyrrhizin and ginsenoside-
Rh2 have been reported to endow estrogenic properties
[48]. Indeed, ginsenoside-Rh2 has been shown to trans-
activate the ERα in MCF-7, and its effect was abrogated
by the pure antiestrogen faslodex (ICI 182,780), suggest-
ing that its effects are primarily mediated by ERs [49]. It
was observed a decrease in the proliferative effect of
compounds with increasing concentrations (from 0.1 to
10 μM), while they did not induce cytotoxicity at con-
centration 10 fold higher, avoiding the hypothesis of the
cytotoxicity at these concentrations. However, the results
obtained with 3 in MCF-7 cells proliferation assay are in
accordance with those observed in the reporter gene
assay. In fact, such as in MCF-7 cells proliferation, it
was noted a concentration-dependent decrease in the
transactivation induced by 3 in ERα. This result strongly
suggests a down regulation phenomenon rather than a
cytotoxicity of these compounds. This phenomenon is
common with phytoestrogen [50]. In addition, belutin a
triterpernoid, structurally related to 2 and 3 have shown
estrogenic activity in MCF-7 cells [51]. It is noteworthy
that 2 has osteogenic properties in vitro [52]; which can
account for beneficial effects of M. macrophylla in post-
menopausal osteoporosis.
Besides their estrogenic properties, phytoestrogens
exert a wide variety of pharmacological effects including
cytotoxicity [10]. Estrogen receptors are one of the tar-
gets in anti-breast cancer therapy. For this reason the
cytotoxic potential of compounds from M. macrophylla
was assessed. It was noted that 2 induced cytotoxic ef-
fects on MCF-7 (CC50 = 110 μM) and MDA-MB-231
(CC50 = 160 μM) cells. This result is in accordance with
some reports [53, 54]. Weak cytotoxic effects were also
observed with 6, 7, 8, 13 and PF. These results are con-
sistent with some reports which postulate that phytoes-
trogens may exert two opposite actions depending on
their concentrations [55]. At lower concentrations
(<10 μM), some phytoestrogens, like genistein, stimulate
growth of ER positive MCF-7 cells, but not the ER nega-
tive MDA-MB-231 breast cancer cells. At higher con-
centrations survival of both types of breast cancer cells
decreases. It was postulate that at the lower concentra-
tion, phytoestrogens acted as ligands of ERs and stimu-
late metabolic pathways, which in turn induced cell
proliferation. However, at higher concentrations, mecha-
nisms which are not dependent on ER pathway such as
antioxidant properties of the flavonoids seem to be trig-
gered [55]. The above arguments might also explain why
MDA-MB-231 cells were found most sensitive than
B CA
D
Fig. 5 Effects of a 3-day treatment with M. macrophylla phenolic fraction on the uterine wet weight (a), total protein levels in uterine (b), uterine
epithelial height (c) and microphotographs (d). OVX = OVX animals treated with the vehicle; E2B = OVX animals treated with estradiol benzoate at
2 μg/kg BW; PF = OVX animals treated with the Millettia macrophylla phenolic extract; MeOH = OVX animals treated with the methanol extract of
M. macrophylla. *p < 0.05, **p < 0.01; ***p < 0.001 as compared with OVX control. Lu: uterine lumen; En: Endometrium; St: Stroma
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MCF-7 cells to M. macrophylla isolates in this study;
they could induce their cytotoxicity by a non-dependent
ER pathway.
The E-screen assay measures the direct estrogenicity
at the target cell level whereas, in animal studies there
are a complexity of several systems and processes in-
volved, including metabolism and clearance. Hence, in
this study, the phenolic fraction of M. macrophylla has
been tested in vivo as a whole of all the isolates.
Estrogenic effects of M. macrophylla phenolic fraction
were assessed in vitro and in vivo. In vitro it can be seen
that phenolic fraction exhibited estrogenic activity but
this effect seems to be lower than the ones induced by
pure compounds. This can be explained by the
phenomenon of the extract dynamic and molecules in-
teractions [56]. As for the pure compounds, the MCF-7
cells proliferation induced by phenolic fraction of M.
macrophylla decreased with increasing concentrations.
Fig. 6 Effects of a 3-day treatment with Millettia macrophylla phenolic fraction on the vaginal epithelium: microphotographs (a) and epithelial height
(b). OVX =OVX animals treated with the vehicle; E2B = OVX animals treated with estradiol benzoate at 2 μg/kg BW; PF = OVX animals treated with
Millettia macrophylla phenolic fraction; MeOH =OVX animals treated with the methanol extract of M. macrophylla. *p < 0.05, **p < 0.01, ***p < 0.01 as
compared with control. Lv = vaginal lumen, Co = stratum corneum, Gr = stratum granulosum, Ge = stratum germinativum, St: Stroma
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It has also been observed that the ability of the M.
macrophylla phenolic fraction to transactivate ERs in re-
porter gene assay change with concentration. However,
the M. macrophylla phenolic fraction induced a most
potent transactivation of ERα as well as ERβ at the lower
concentrations (10−3 and 10−2 μg/mL) than that previ-
ously reported with methanol crude extract (10−1 and
101 μg/mL) [18]. The in vivo estrogenic activity of this
fraction was assessed in an uterotrophic assay. Phenolic
fraction at the dose of 10 mg/kg induced a significant in-
crease in uterine wet weight, uterine total protein level,
vaginal and uterine epithelial height as well as in mam-
mary glands differentiation. These results confirm those
previously obtained with M. macrophylla methanol ex-
tract on estrogen target organs [18]. However, as ob-
served in reporter gene assay, the obtained results
indicate that the phenolic fraction is more efficient than
the crude methanol extract. We can hypothesized that 6,
13, 10, 11, 3 as well as others potential active principles
detected in M. macrophylla phenolic fraction are able to
transactivate the ERα as observed in the reported gene
assay and trigger proliferation of vaginal and uterine epi-
thelial cells as it did in MCF-7 cells in vitro. Such effects
have been reported to be mediated by ERα [57]. Cell
proliferation is followed by protein synthesis increased;
this can explain the observed increased of total protein
level in uterus after 3 consecutive days of treatment. Au-
thors report that this increase in protein amounts into
cells is responsible for the uterine wet imbibition [58].
Conversely, the increase in the acini size of mammary
gland observed in vivo with the M. macrophylla phen-
olic fraction, can be explained by the capacity of this
fraction to induce MCF-7 cells proliferation, which are
adenocarcinoma cells expressing ERα. Further, PF in-
duced a weak cytotoxic activity in both MCF-7 and
MDA-MB-231 cells. This result can be a promising
search of anti-breast cancer therapy.
The most common concern in postmenopausal
women is hot flushes which are experienced by as many
as 75 % of menopausal women [59]. It is well docu-
mented that the effectiveness of xenobiotic in compen-
sating the effects of estrogen deprivation can be assessed
by its ability to alleviate hot flushes [60]. It appears from
the analysis of core temperatures that, the average dur-
ation and frequency of hot flushes was significantly re-
duced in the group treated with the phenolic fraction at
the dose of 10 mg/kg. All these results suggest that this
fraction contains secondary metabolites with estrogenic
activity which can reverse the thermoregulatory dysfunc-
tion related to post-oophorectomy depletion of endogen-
ous estrogens. Indeed, Freedman et al. [59] reported that
estrogen and estrogenic substances raise the sweating
threshold and expand the thermoneutral area in post-
menopausal symptomatic women.
Conclusion
Millettia macrophylla has estrogenic properties, given
its high amount of flavonoids as well as triterpernoids
mainly, variabilin (13), aformorsin (7), pisatin (10), stig-
mastenone (3), flemichaparin B (11), formononetin (6),
Fig. 7 Effects of a 3-day treatment with M. macrophylla extracts on mammary gland. OVX =OVX animals treated with the corn oil; E2B = OVX animals
treated with estradiol benzoate 2 μg/kg BW; PF = OVX animals treated with the Millettia macrophylla phenolic fraction; MeOH =OVX animals treated
with the methanol extract of M. macrophylla. La = lumen of alveoli; Ep = aveoli epitheluim; At = adipose tissue; Se = eosinophil secretion
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Fig. 8 Effects of a 3-day treatment with Millettia macrophylla phenolic fraction on total number (a), average duration (b) and frequency (c) of hot
flushes. Sham = Sham operated rats treated with the vehicle (corn oil); OVX = OVX animals treated with the vehicle (corn oil); E2B = OVX animals
treated with estradiol benzoate at 2 μg/kg BW; PF = OVX animals treated with Millettia macrophylla phenolic fraction. * p < 0.05, ** p < 0.01 as
compared to control. # p < 0.05, ## p < 0.01 as compared to Sham
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lupeol (2), which exhibited estrogenic effects in this
work. 11, 3 and 2 have been described for the first time
as estrogenic in this work and together with 7, 13, 10
and 6 could be the active principles of M. macrophylla.
The phenolic fraction prepared from methanol extract
of M. macrophylla appears to be more efficient than the
methanol crude extract. It could be a good candidate for
the preparation of an improved traditional medicine
from M. macrophylla able to alleviate some menopausal
complaints such as vaginal dryness and hot flushes.
However, further studies have to be developed to achieve
a better understanding concerning the interactions be-
tween the ligand-receptor binding of these compounds
and ERs.
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